Federal Court of Appeal remits pricing decision on Alexion's Soliris to Patented Medicine ...

Retrieved on: 2021-09-08 00:00:00

Tags for this article:

Click the tags to see associated articles and topics

Federal Court of Appeal remits pricing decision on Alexion's Soliris to Patented Medicine .... View article details on hiswai:

Excerpt

In September 2017 the Patented Medicine Prices Review Board (the board) decided that Alexion's Soliris (eculizumab) was sold at an excessive price.

Article found on: www.lexology.com